LipReg4 Gene Deletion Prevents Salt-Induced Hypertension
The mutation stops alpha-lipomycin production, confirming its role in blood pressure regulation.
Updated on Oct. 16, 2026 in Life Sciences
Researchers have successfully engineered a mutant strain of Streptomyces aureofaciens Tü117 that cannot produce the molecule alpha-lipomycin. This genetic modification research demonstrates that alpha-lipomycin production is required for the bacteria to induce sustained high blood pressure.
Why it matters
The study clarifies the role of specific bacterial metabolites in salt-induced hypertension, distinguishing between the presence of the bacteria itself and the chemical products it synthesizes.
Using CRISPR-Cas9 genome editing, researchers deleted the LipReg4 gene in Streptomyces aureofaciens Tü117, successfully abolishing alpha-lipomycin biosynthesis without impacting baseline bacterial growth.
The players
Streptomyces aureofaciens Tü117
A bacterial strain implicated in high-salt-induced hypertension through the production of alpha-lipomycin.
The details
Alpha-lipomycin is a metabolite that acts as a TRPV4 antagonist—a chemical that blocks the transient receptor potential vanilloid 4 ion channel—which impairs vasodilation, or the widening of blood vessels. By using CRISPR-Cas9 to delete the LipReg4 gene, the researchers created a strain (ΔTü117) that specifically stops producing this antagonist. This experiment isolates the metabolite's function from the bacterium's presence, showing that the molecule, rather than the bacteria alone, triggers sustained hypertension.
Timeline
October 16, 2026: The research findings were published.
The Tech Race
This study advances the gut microbiome-hypertension research program by pinpointing alpha-lipomycin as a specific causal metabolite. It follows a growing pattern of efforts to move from correlation to causation by isolating precise microbial molecules implicated in chronic host conditions.
This research is currently in the experimental stage and does not change clinical practice or immediate diagnostic testing for patients. It serves as a foundational step toward identifying potential therapeutic targets for managing salt-induced hypertension.
The takeaway
The study establishes that alpha-lipomycin is the key driver of hypertension linked to this bacterial strain, providing a clear target for future molecular interventions. Future research will likely focus on whether blocking this specific metabolic pathway in the gut can prevent blood pressure elevation in vivo.
Further reading
For more research on how microbial activity influences chronic health conditions, see the latest in Life Sciences.
Source note: This article includes information reported by Nature.
